Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies

References

• Luger K , Mader AW , Richmond RK , Sargent DF , Richmond TJ . Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997;389:251–260.
   PubMed Web of Science ®Google Scholar
• Bannister AJ , Kouzarides T . Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–395.10.1038/cr.2011.22
   PubMed Web of Science ®Google Scholar
• Zhang Y , Reinberg D . Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Gen Develop. 2001;15:2343–2360.
   PubMed Web of Science ®Google Scholar
• Nowak SJ , Corces VG . Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 2004;20:214–220.10.1016/j.tig.2004.02.007
   PubMed Web of Science ®Google Scholar
• Weake VM , Workman JL . Histone ubiquitination: triggering gene activity. Mol Cell. 2008;29:653–663.10.1016/j.molcel.2008.02.014
   PubMed Web of Science ®Google Scholar
• Kurdistani SK , Grunstein M . Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol. 2003;4:276–284.10.1038/nrm1075
   PubMed Web of Science ®Google Scholar
• Ropero S , Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25.10.1016/j.molonc.2007.01.001
   PubMed Web of Science ®Google Scholar
• Rivieccio MA , Brochier C , Willis DE , Walker BA , D’Annibale MA , McLaughlin K , et al . HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA. 2009;106:19599–19604.10.1073/pnas.0907935106
   PubMed Web of Science ®Google Scholar
• Ganai SA . Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem. 2016;16:427–434.
   PubMed Web of Science ®Google Scholar
• Ganai SA , Ramadoss M , Mahadevan V . Histone deacetylase (HDAC) inhibitors – emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr Neuropharmacol. 2015;14:55–71.
   Web of Science ®Google Scholar
• de Ruijter AJ , van Gennip AH , Caron HN , Kemp S , van Kuilenburg AB . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–749.10.1042/bj20021321
   PubMed Web of Science ®Google Scholar
• Kijima M , Yoshida M , Sugita K , Horinouchi S , Beppu T . Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 1993;268:22429–22435.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MP , Kato T , Okauchi T , Nishino N , Maeda S , Nishino TG , et al . Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem. 2006;14:3438–3446.
   PubMed Web of Science ®Google Scholar
• Ganai SA . Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Arch Pharm Res. 2015;1–11.
   Google Scholar
• Finnin MS , Donigian JR , Cohen A , Richon VM , Rifkind RA , Marks PA , et al . Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401:188–193.
   PubMed Web of Science ®Google Scholar
• Ganai SA , Shanmugam K , Mahadevan V . Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms. J Biomol Struct Dyn. 2015;33:374–387.
   PubMed Web of Science ®Google Scholar
• Mottamal M , Zheng S , Huang TL , Wang G . Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–941.
   PubMed Web of Science ®Google Scholar
• Khan N , Jeffers M , Kumar S , Hackett C , Boldog F , Khramtsov N , et al . Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409:581–589.10.1042/BJ20070779
   PubMed Web of Science ®Google Scholar
• Ganai S . In silico approaches towards safe targeting of class I histone decetylases. Mol Life Sci. 2015;1–9.
   Google Scholar
• Cao DJ , Wang ZV , Battiprolu PK , Jiang N , Morales CR , Kong Y , et al . Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA. 2011;108:4123–4128.10.1073/pnas.1015081108
   PubMed Web of Science ®Google Scholar
• Zhang CZ , Zhang HT , Chen GG , Lai PB . Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis. 2011;16:683–695.10.1007/s10495-011-0597-x
   PubMed Web of Science ®Google Scholar
• Galmozzi A , Mitro N , Ferrari A , Gers E , Gilardi F , Godio C , et al . Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes. 2013;62:732–742.10.2337/db12-0548
   PubMed Web of Science ®Google Scholar
• Shao Y , Gao Z , Marks PA , Jiang X . Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2004;101:18030–18035.10.1073/pnas.0408345102
   PubMed Web of Science ®Google Scholar
• Colussi C , Mozzetta C , Gurtner A , Illi B , Rosati J , Straino S , et al . HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2008;105:19183–19187.10.1073/pnas.0805514105
   PubMed Web of Science ®Google Scholar
• Jones J , Juengel E , Mickuckyte A , Hudak L , Wedel S , Jonas D , et al . The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009;13:2376–2385.10.1111/j.1582-4934.2008.00436.x
   PubMed Web of Science ®Google Scholar
• Johannessen CU , Johannessen SI . Valproate: past, present, and future. CNS Drug Rev. 2003;9:199–216.
   PubMedGoogle Scholar
• Gibbs A , Schwartzman J , Deng V , Alumkal J . Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA. 2009;106:16663–16668.10.1073/pnas.0908908106
   PubMed Web of Science ®Google Scholar
• Ververis K , Hiong A , Karagiannis TC , Licciardi PV . Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013;7:47–60.
   PubMedGoogle Scholar
• Chun P . Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res. 2015;38:933–949.10.1007/s12272-015-0571-1
   PubMed Web of Science ®Google Scholar
• Leoni F , Fossati G , Lewis EC , Lee JK , Porro G , Pagani P , et al . The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11:1–15.10.2119/2006-00005.Dinarello
   PubMed Web of Science ®Google Scholar
• Armeanu S , Pathil A , Venturelli S , Mascagni P , Weiss TS , Göttlicher M , et al . Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol. 2005;42:210–217.10.1016/j.jhep.2004.10.020
   PubMed Web of Science ®Google Scholar
• Carta S , Tassi S , Semino C , Fossati G , Mascagni P , Dinarello CA , et al . Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 2006;108:1618–1626.10.1182/blood-2006-03-014126
   PubMed Web of Science ®Google Scholar
• Glauben R , Batra A , Stroh T , Erben U , Fedke I , Lehr HA , et al . Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 2008;57:613–622.10.1136/gut.2007.134650
   PubMed Web of Science ®Google Scholar
• Lewis EC , Blaabjerg L , Størling J , Ronn SG , Mascagni P , Dinarello CA , et al . The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol Med. 2011;17:369–377.
   PubMed Web of Science ®Google Scholar
• Libby EN , Becker PS , Burwick N , Green DJ , Holmberg L , Bensinger WI . Panobinostat: a review of trial results and future prospects in multiple myeloma. Exp Rev Hematol. 2015;8:9–18.10.1586/17474086.2015.983065
   PubMed Web of Science ®Google Scholar
• Mateos MV , Ocio EM , San Miguel JF . Novel generation of agents with proven clinical activity in multiple myeloma. Sem Oncol. 2013;40:618–633.10.1053/j.seminoncol.2013.07.005
   PubMed Web of Science ®Google Scholar
• Galli M , Salmoiraghi S , Golay J , Gozzini A , Crippa C , Pescosta N , et al . A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol. 2010;89:185–190.10.1007/s00277-009-0793-8
   PubMed Web of Science ®Google Scholar
• Golay J , Cuppini L , Leoni F , Micò C , Barbui V , Domenghini M , et al . The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21:1892–1900.10.1038/sj.leu.2404860
   PubMed Web of Science ®Google Scholar
• Todoerti K , Barbui V , Pedrini O , Lionetti M , Fossati G , Mascagni P , et al . Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica. 2010;95:260–269.10.3324/haematol.2009.012088
   PubMed Web of Science ®Google Scholar
• Pichiorri F , Suh SS , Ladetto M , Kuehl M , Palumbo T , Drandi D , et al . MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–12890.10.1073/pnas.0806202105
   PubMed Web of Science ®Google Scholar
• Rambaldi A , MC , Cuppini L , et al . The new histone deacetylase inhibitor ITF2357 is a strong inducer of apoptosis in multiple myeloma cells. Presented at: 10th Congress of the European Hematology Association; Stockholm, Sweden, 2005 June 2–5. Abstract 0230.
   Google Scholar
• Ganai SA . HDAC inhibitors entinostat and suberoylanilide hydroxamic acid (SAHA): the ray of hope for cancer therapy. Mol Life Sci. 2015;1–16.
   Google Scholar
• Morrison R , Schleicher SM , Sun Y , Niermann KJ , Kim S , Spratt DE , et al . Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876.
   PubMedGoogle Scholar
• Galimberti S , Canestraro M , Savli H , Palumbo GA , Tibullo D , Nagy B , et al . ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. Anticancer Res. 2010;30:4525–4535.
   PubMed Web of Science ®Google Scholar
• Cilloni D , Messa F , Arruga F , Defilippi I , Gottardi E , Fava M , et al . Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93:921–924.10.3324/haematol.12165
   PubMed Web of Science ®Google Scholar
• Barbetti V , Gozzini A , Rovida E , Morandi A , Spinelli E , Fossati G , et al . Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene. 2008;27:1767–1778.10.1038/sj.onc.1210820
   PubMed Web of Science ®Google Scholar
• Leoni F , Mascagni P . Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments. Google Patents; 2012.
   Google Scholar
• Zappasodi R , Cavanè A , Iorio MV , Tortoreto M , Guarnotta C , Ruggiero G , et al . Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. Int J Cancer. 2014;135:2034–2045.10.1002/ijc.28852
   PubMed Web of Science ®Google Scholar
• Viviani SBV , Fasola C , Valagussa P , Gianni AM , Viviani S , Bonfante V , et al . Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patients. ASCO Meeting Abstracts. 2008;26:8532.
   Google Scholar
• Carlo-Stella CGA , Viviani S , et al . Phase II trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/refractory Hodgkin Lymphoma (HL). Blood. 2008;112:2586.
   Web of Science ®Google Scholar
• Buglio D , Younes A . Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs. 2010;28:21–27.10.1007/s10637-010-9588-y
   PubMed Web of Science ®Google Scholar
• Locatelli SL , Cleris L , Stirparo GG , Tartari S , Saba E , Pierdominici M , et al . BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia. 2014;28:1861–1871.
   PubMed Web of Science ®Google Scholar
• Tefferi A . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012;119:2721–2730.10.1182/blood-2011-11-395228
   PubMed Web of Science ®Google Scholar
• Guerini V , Barbui V , Spinelli O , Salvi A , Dellacasa C , Carobbio A , et al . The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia. 2008;22:740–747.10.1038/sj.leu.2405049
   PubMed Web of Science ®Google Scholar
• Rambaldi A , Dellacasa CM , Finazzi G , Carobbio A , Ferrari ML , Guglielmelli P , et al . A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Brit J Haematol. 2010;150:446–455.
   PubMed Web of Science ®Google Scholar
• Barbui T , Barosi G , Birgegard G , Cervantes F , Finazzi G , Griesshammer M , et al . Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–770.10.1200/JCO.2010.31.8436
   PubMed Web of Science ®Google Scholar
• Barosi G , Birgegard G , Finazzi G , Griesshammer M , Harrison C , Hasselbalch H , et al . A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Brit J Haematol. 2010;148:961–963.10.1111/bjh.2010.148.issue-6
   PubMed Web of Science ®Google Scholar
• Finazzi G , Vannucchi AM , Martinelli V , Ruggeri M , Nobile F , Specchia G , et al . A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Brit J Haematol. 2013;161:688–694.10.1111/bjh.2013.161.issue-5
   PubMed Web of Science ®Google Scholar